1.87
Gain Therapeutics Inc (GANX) 最新ニュース
How to build a dashboard for Gain Therapeutics Inc. stockTrade Analysis Report & Daily Risk Controlled Trade Plans - newser.com
How Gain Therapeutics Inc. stock reacts to inflationary pressuresJuly 2025 Action & Daily Profit Focused Screening - Trung tâm Dự báo KTTV quốc gia
Is Gain Therapeutics Inc. stock a defensive play in 2025Market Sentiment Report & Precise Trade Entry Recommendations - Trung tâm Dự báo KTTV quốc gia
Gain Therapeutics’ (GANX) Buy Rating Reiterated at BTIG Research - Defense World
How to forecast Gain Therapeutics Inc. trends using time series2025 Analyst Calls & AI Driven Stock Reports - newser.com
Is Gain Therapeutics Inc. still worth holding after the dipWeekly Profit Report & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Gain Therapeutics Inc. stock entering bullish territoryEarnings Recap Report & Low Risk Entry Point Tips - newser.com
Gain Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Custom strategy builders for tracking Gain Therapeutics Inc.July 2025 Big Picture & Community Consensus Trade Signals - newser.com
Is Gain Therapeutics Inc a good long term investmentEarnings Miss Alerts & Exceptional Growth Portfolio - earlytimes.in
Gain Therapeutics to Attend the 2025 Maxim Growth Summit - The Manila Times
Oct 22: Gene Mack to Speak — Gain Therapeutics at 2025 Maxim Growth Summit on Neurodegenerative Panel - Stock Titan
What recovery options are there for Gain Therapeutics Inc.Quarterly Growth Report & Weekly High Return Opportunities - newser.com
BTIG Reiterates Gain Therapeutics (GANX) Buy Recommendation - Nasdaq
Intraday pattern recognizer results for Gain Therapeutics Inc.Buy Signal & Community Verified Trade Alerts - newser.com
Institutional scanner results for Gain Therapeutics Inc.July 2025 Chart Watch & Reliable Momentum Entry Alerts - newser.com
Gain Therapeutics, Inc Hosts Key Opinion Leader Event on GT-02287 - TradingView
Gain Therapeutics (NASDAQ:GANX) Given “Buy” Rating at HC Wainwright - Defense World
How risky is Gain Therapeutics Inc. stock nowJuly 2025 Patterns & Entry and Exit Point Strategies - newser.com
Certain Options of Gain Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-OCT-2025. - MarketScreener
Certain Common Stock of Gain Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-OCT-2025. - MarketScreener
Will Gain Therapeutics Inc. stock benefit from sector rotationEarnings Trend Report & Weekly High Return Forecasts - newser.com
HC Wainwright & Co. Reiterates Gain Therapeutics (GANX) Buy Recommendation - Nasdaq
What does recent volatility data suggest for Gain Therapeutics Inc.Earnings Miss & High Return Trade Opportunity Guides - newser.com
Published on: 2025-10-10 04:06:35 - newser.com
Eric Richman Resigns from Gain Therapeutics Board - TipRanks
Allosteric small molecule therapies in PD, with Gene Mack - pharmaphorum
Is Gain Therapeutics Inc. stock cheap at current valuationBreakout Watch & Daily Stock Trend Watchlist - newser.com
Is it time to cut losses on Gain Therapeutics Inc.2025 Momentum Check & Free Expert Verified Stock Movement Alerts - newser.com
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease - The Manila Times
Gain Therapeutics to Host Virtual KOL Event on GT-02287 and Parkinson's Disease Research - Quiver Quantitative
Applying big data sentiment scoring on Gain Therapeutics Inc.Weekly Gains Report & AI Driven Price Forecasts - newser.com
Gain Therapeutics (NASDAQ:GANX) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Gain Therapeutics Supports Reliable Data Management In Labs - Kalkine Media
Gain Therapeutics (NASDAQ:GANX) Given New $7.00 Price Target at Maxim Group - Defense World
Maxim Group Maintains Gain Therapeutics (GANX) Buy Recommendation - Nasdaq
Maxim Group Raises Price Target for Gain Therapeutics (GANX) to - GuruFocus
Gain Therapeutics reports preliminary Phase 1b data for Parkinson’s drug GT-02287 - Investing.com
Stock Traders Buy High Volume of Gain Therapeutics Call Options (NASDAQ:GANX) - MarketBeat
Gain Therapeutics reports positive early data from Parkinson’s trial - Investing.com
Gain Therapeutics reports positive early data from Parkinson’s trial By Investing.com - Investing.com Australia
Gain Therapeutics Reports Positive Interim Data from Phase 1b Study of GT-02287 in Parkinson’s Disease - Quiver Quantitative
Gain Therapeutics' GT-02287 Shows UPDRS Improvement in 9 by Day 90 | GANX Stock News - Stock Titan
What to do if you’re stuck in Gain Therapeutics Inc.Breakout Watch & Daily Stock Trend Watchlist - newser.com
大文字化:
|
ボリューム (24 時間):